For the quarter ending 2026-03-31, ATOS had -$9,581K decrease in cash & cash equivalents over the period. -$9,581K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -9,589 | -10,937 | -8,692 | -15,141 |
| Stock-based compensation | 722 | 503 | 784 | 1,359 |
| Loss on disposal of assets | - | 0 | 0 | 0 |
| Impairment charge on investment in equity securities | - | 0 | 0 | - |
| Depreciation | 4 | 4 | 4 | 8 |
| Prepaid materials | -68 | -62 | -332 | 1,377 |
| Prepaid expenses and other current assets | 699 | 548 | -495 | -90 |
| Other assets | -711 | -343 | 329 | 10 |
| Accounts payable | -1,724 | 761 | 1,522 | 1,331 |
| Accrued expenses | 1,500 | -682 | -211 | 1,281 |
| Payroll liabilities | -615 | 433 | 71 | -808 |
| Other current liabilities | 41 | -478 | 19 | 49 |
| Net cash used in operating activities | -9,581 | -10,539 | -6,005 | -13,218 |
| Purchases of property and equipment | 0 | 7 | 7 | 9 |
| Net cash used in investing activities | 0 | -7 | -7 | -9 |
| Proceeds from exercise of warrants | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 | 0 | 0 |
| Net decrease in cash, cash equivalents and restricted cash | -9,581 | -10,546 | -6,012 | -13,227 |
| Cash, cash equivalents and restricted cash, beginning balance | 41,409 | 71,194 | 71,194 | - |
| Cash, cash equivalents and restricted cash, ending balance | 31,828 | -10,546 | 51,955 | - |
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)